The latest price target for Senti Biosciences (NASDAQ:SNTI) was reported by Chardan Capital on December 4, 2024. The analyst firm set a price target for $12.00 expecting SNTI to rise to within 12 months (a possible 197.77% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Senti Biosciences (NASDAQ:SNTI) was provided by Chardan Capital, and Senti Biosciences maintained their buy rating.

There is no last upgrade for Senti Biosciences

There is no last downgrade for Senti Biosciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Senti Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Senti Biosciences was filed on December 4, 2024 so you should expect the next rating to be made available sometime around December 4, 2025.

While ratings are subjective and will change, the latest Senti Biosciences (SNTI) rating was a maintained with a price target of $10.00 to $12.00. The current price Senti Biosciences (SNTI) is trading at is $4.03, which is out of the analyst’s predicted range.